MARKET

PFE

PFE

Pfizer
NYSE
26.27
-0.05
-0.19%
Pre Market: 26.25 -0.02 -0.08% 05:36 04/25 EDT
OPEN
26.25
PREV CLOSE
26.32
HIGH
26.34
LOW
26.04
VOLUME
467
TURNOVER
0
52 WEEK HIGH
40.37
52 WEEK LOW
25.23
MARKET CAP
148.75B
P/E (TTM)
70.77
1D
5D
1M
3M
1Y
5Y
UPDATE 2-Ad group WPP trails rivals with decline in organic revenue
UK ad group WPP trails rivals with decline in organic revenue in first quarter. UK group lags rivals Publicis, Omnicom and IPG which reported improving revenue. CEO Mark Read says Q2 will be 'little bit better' than first quarter, shares fall 2.7%. WPP hurt by lower tech spending, downturn in China and loss of business from Pfizer.
Reuters · 3h ago
Will Higher Keytruda Sales Drive Merck's Q1
NASDAQ · 8h ago
Pfizer declares $0.42 dividend
Dividend Stocks News Pfizer declares $0.42 dividend Apr. 24, 2024 4:38 PM ETPfizer Inc. (PFE) Stock. Forward yield 6.4% Payable June 14; for shareholders of record May 10; ex-div May 9.
Seeking Alpha · 13h ago
PFIZER INC - DECLARED A $0.42 SECOND-QUARTER 2024 DIVIDEND ON COMPANY'S COMMON STOCK
Reuters · 13h ago
Press Release: Pfizer Declares Second-Quarter 2024 Dividend
Pfizer Declares Second-Quarter 2024 Dividend Board of Directors approves quarterly cash dividend of $0.42 per share. The second-quarter 2024 cash dividend will be the 342nd consecutive quarterly dividend paid by Pfizer. The dividend is payable June 14, 2024, to holders of the company's common stock.
Dow Jones · 13h ago
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
NASDAQ · 18h ago
Pfizer Declares Second-Quarter 2024 Dividend
The second-quarter 2024 cash dividend will be the 342nd consecutive quarterly dividend paid by Pfizer. The dividend is payable June 14, 2024, to holders of the company's common stock of record on May 10, 2024. Pfizer's board of directors declared a $0.42 second- quarterly 2024 dividend.
Barchart · 18h ago
PFIZER CANADA: HEALTH CANADA HAS GRANTED A NOTICE OF COMPLIANCE (NOC) FOR VELSIPITY™
Reuters · 19h ago
More
About PFE
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

Webull offers Pfizer Inc stock information, including NYSE: PFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PFE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PFE stock methods without spending real money on the virtual paper trading platform.